FHL2 Determines Poor Outcomes and Responsiveness of Immunotherapy Plus Tyrosine Kinase Inhibition in Metastatic Renal Cell Carcinoma
-
Published:2024
Issue:
Volume:
Page:216-224
-
ISSN:2822-2288
-
Container-title:Eurasian Journal of Medical Advances
-
language:
-
Short-container-title:EJMA
Publisher
Kare Publishing